XML 36 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
 9 Months Ended
Sep. 30, 2012
Segment Reporting [Abstract]  
Operating Segment And Geographic Information
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
Our chief operating decision-maker is our Chief Executive Officer, who regularly evaluates our performance based on net sales and net loss before taxes. The preparation of this segment analysis requires management to make estimates and assumptions around expenses below the gross profit level. While we believe the segment information to be directionally correct, actual results could differ from the estimates and assumptions used in preparing this information.
The accounting policies of the segments are the same as the policies discussed in Footnote B – Summary of Significant Accounting Policies.
We have three reportable operating segments, Clinical Laboratories, Pharmacogenomic Services and Diagnostic Tools.
 
Segment information for the three months ended September 30, 2012 and 2011 is as follows:
 
 
Dollars in Thousands
 
2012
 
Clinical Laboratories
 
Pharmacogenomic Services
 
Diagnostic
Tools
 
Total
Net Sales
$
4,498

 
$
220

 
$
3,171

 
$
7,889

Gross Profit
2,385

 
(38
)
 
1,453

 
3,800

Net Loss before Taxes
(1,694
)
 
(213
)
 
(733
)
 
(2,640
)
Income Tax Expense
—

 
—

 
114

 
114

Net Loss
$
(1,694
)
 
$
(213
)
 
$
(847
)
 
$
(2,754
)
Depreciation/Amortization
$
418

 
$
24

 
$
53

 
$
495

Interest Expense, net
$
(201
)
 
$
—

 
$
(6
)
 
$
(207
)
 
 
 
 
 
 
 
 
 
September 30, 2012
Total Assets
$
28,822

 
$
1,731

 
$
12,334

 
$
42,887



 
 
 
 
 
 
 
 
 
Dollars in Thousands
 
2011
 
Clinical Laboratories
 
Pharmacogenomic Services
 
Diagnostic
Tools
 
Total
Net Sales
$
4,085

 
$
552

 
$
3,616

 
$
8,253

Gross Profit
2,456

 
241

 
1,748

 
4,445

Net Income (Loss) before Taxes
(1,472
)
 
122

 
71

 
(1,279
)
Income Tax Expense (Benefit)
(20
)
 
—

 
11

 
(9
)
Net Income (Loss)
$
(1,452
)
 
$
122

 
$
60

 
$
(1,270
)
Depreciation/Amortization
$
350

 
$
75

 
$
56

 
$
481

Restructure
$
2

 
$
—

 
$
3

 
$
5

Interest Expense, net
$
(238
)
 
$
—

 
$
—

 
$
(238
)
 
 
 
 
 
 
 
 
 
September 30, 2011
Total Assets
$
20,822

 
$
953

 
$
8,199

 
$
29,974



Segment information for the nine months ended September 30, 2012 and 2011 is as follows:
 
Dollars in Thousands
 
2012
 
Clinical Laboratories
 
Pharmacogenomic Services
 
Diagnostic
Tools
 
Total
Net Sales
$
13,329

 
$
1,198

 
$
9,661

 
$
24,188

Gross Profit
6,693

 
418

 
4,355

 
11,466

Net Loss before Taxes
(4,309
)
 
(310
)
 
(1,307
)
 
(5,926
)
Income Tax Expense
—

 
—

 
88

 
88

Net Loss
$
(4,309
)
 
$
(310
)
 
$
(1,395
)
 
$
(6,014
)
Depreciation/Amortization
$
1,265

 
$
92

 
$
213

 
$
1,570

Restructure
$
—

 
$
—

 
$
—

 
$
—

Interest Expense, net
$
(665
)
 
$
(11
)
 
$
(37
)
 
$
(713
)
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
 
 
Dollars in Thousands
 
2011
 
Clinical Laboratories
 
Pharmacogenomic Services
 
Diagnostic
Tools
 
Total
Net Sales
$
11,435

 
$
1,824

 
$
10,141

 
$
23,400

Gross Profit
6,787

 
764

 
5,601

 
13,152

Net Income (Loss) before Taxes
(11,331
)
 
615

 
551

 
(10,165
)
Income Tax Benefit
—

 
—

 
(120
)
 
(120
)
Net Income (Loss)
$
(11,331
)
 
$
615

 
$
671

 
$
(10,045
)
Depreciation/Amortization
$
1,113

 
$
184

 
$
209

 
$
1,506

Restructure
$
28

 
$
—

 
$
12

 
$
40

Interest Expense, net
$
(720
)
 
$
—

 
$
—

 
$
(720
)
 
 
 
 
 
 
 
 

 
Net sales for the three and nine months ended September 30, 2012 and 2011 by country were as follows:
 
 
Dollars in Thousands
 
Dollars in Thousands
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2012
 
2011
 
2012
 
2011
United States
$
5,442

 
$
6,034

 
$
17,013

 
$
16,738

Italy
571

 
762

 
2,277

 
2,373

United Kingdom
546

 
193

 
1,113

 
451

France
264

 
166

 
575

 
579

Germany
517

 
187

 
769

 
581

All Other Countries
549

 
911

 
2,441

 
2,678

Total
$
7,889

 
$
8,253

 
$
24,188

 
$
23,400


Other than the countries specifically identified above, no other country individually accounted for more than 5% of total net sales.

More than 95% of our long-lived assets are located within the United States.